Wegovy Maker Launches Lower-Cost Subscription Plans

Follow Drugslib on

By HealthDay Staff HealthDay Reporter

Amazon Big Spring Sale - Up to 40% off

Medically reviewed by Carmen Pope, BPharm. Last updated on April 2, 2026.

via HealthDay

THURSDAY, April 2, 2026 — A popular weight loss drug may soon be more affordable for some people.

Danish pharmaceutical company Novo Nordisk has launched a subscription program for its obesity treatment Wegovy, offering lower and more predictable monthly prices.

The program is aimed at those who pay for the medication themselves, The Wall Street Journal reported.

Patients can choose from three-, six- or 12-month plans for the Wegovy injection and two higher-dose pill versions.

Monthly costs for the injection drop to:

  • $329 per month for a three-month subscription
  • $299 per month for six months
  • $249 per month for a 12-month subscription

    • That's about $1,200 in yearly savings on the longest plan, the company said.

    The pill version is a bit cheaper:

  • $289 per month for a three-month subscription
  • $269 per month for six months
  • $249 per month for a year’s subscription

    • That could save patients up to $600 a year.

    The program is available through telehealth platforms including Ro, WeightWatchers and LifeMD.

    More providers like Hims & Hers and Sesame are expected to come online soon.

    Novo Nordisk said the goal is to make costs more predictable and help people stay on treatment.

    "The program is designed to reduce cost uncertainty and help people start and stay on [the] FDA-approved obesity treatment," the company said.

    The subscription plans come as competition grows in the weight-loss medication market. Rival drugmaker Eli Lilly, whose pill secured FDA approval in only 50 days, sells its weight loss injectable Zepbound for about $299 to $449 a month, The Wall Street Journal added.

    Drugmakers are also facing pressure from cheaper copycat versions sold by compounding pharmacies.

    Novo Nordisk has said it plans to lower U.S. prices for Wegovy and its diabetes drug Ozempic starting next year, as it tries to reach more patients.

    Sources

  • The Wall Street Journal, March 31, 2026

    • Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

    Source: HealthDay

    Posted : 2026-04-03 01:52

    Read more

    Disclaimer

    Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

    The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

    Popular Keywords